Luteolin ameliorates lipopolysaccharide-induced microcirculatory disturbance through inhibiting leukocyte adhesion in rat mesenteric venules.
Animals
Cell Adhesion
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Human Umbilical Vein Endothelial Cells
Humans
Leukocytes
/ drug effects
Lipopolysaccharides
/ toxicity
Luteolin
/ pharmacology
Male
Mesentery
/ blood supply
Microcirculation
/ drug effects
Rats
Rats, Sprague-Dawley
THP-1 Cells
LPS
Leukocyte adhesion
Luteolin
Microcirculatory disturbance
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
14 Jan 2021
14 Jan 2021
Historique:
received:
07
08
2020
accepted:
22
12
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
3
9
2021
Statut:
epublish
Résumé
Microcirculatory disturbance is closely associated with multiple diseases such as ischemic and septic stroke. Luteolin (3,4,5,7-tetrahydroxyflavone) is a vascular protective flavonoid present in several dietary foods. However, how luteolin plays a role in microcirculatory disturbance is still unknown. The purpose of this study was to find out the influence of luteolin on the lipopolysaccharide (LPS)-induced microcirculatory disturbance, focusing on its effect on leukocyte adhesion and the underlying mechanism of this effect. After injecting LPS into rats, we used an inverted intravital microscope to observe the velocity of red blood cells in venules, numbers of leukocytes adherent to and emigrated across the venular wall, hydrogen peroxide production in venular walls and mast cell degranulation. Intestinal microcirculation blood flow was measured by High-resolution Laser Doppler Perfusion Imaging. Histological changes of small intestine and mesenteric arteries were evaluated. Additionally, cell adhesion stimulated by LPS was tested on EA.hy926 and THP-1 cells. The production of pro-inflammatory cytokines, adhesion molecules and the activation of TLR4/Myd88/NF-κB signaling pathway were determined. The results showed luteolin significantly inhibited LPS-induced leukocyte adhesion, hydrogen peroxide production and mast cell degranulation, and increased intestinal microcirculation blood flow and ameliorated pathological changes in the mesenteric artery and the small intestine. Furthermore, luteolin inhibited the release of pro-inflammatory cytokines, the expression of TLR4, Myd88, ICAM-1, and VCAM-1, the phosphorylation of IκB-α and NF-κB/p65 in LPS stimulated EA.hy926. Our findings revealed that it is likely that luteolin can ameliorate microcirculatory disturbance. The inhibitory effects of luteolin on the leukocyte adhesion stimulated by LPS, which participates in the development of microcirculatory disturbance, are mediated through the regulation of the TLR4/Myd88/NF-κB signaling pathway.
Sections du résumé
BACKGROUND
BACKGROUND
Microcirculatory disturbance is closely associated with multiple diseases such as ischemic and septic stroke. Luteolin (3,4,5,7-tetrahydroxyflavone) is a vascular protective flavonoid present in several dietary foods. However, how luteolin plays a role in microcirculatory disturbance is still unknown. The purpose of this study was to find out the influence of luteolin on the lipopolysaccharide (LPS)-induced microcirculatory disturbance, focusing on its effect on leukocyte adhesion and the underlying mechanism of this effect.
METHODS
METHODS
After injecting LPS into rats, we used an inverted intravital microscope to observe the velocity of red blood cells in venules, numbers of leukocytes adherent to and emigrated across the venular wall, hydrogen peroxide production in venular walls and mast cell degranulation. Intestinal microcirculation blood flow was measured by High-resolution Laser Doppler Perfusion Imaging. Histological changes of small intestine and mesenteric arteries were evaluated. Additionally, cell adhesion stimulated by LPS was tested on EA.hy926 and THP-1 cells. The production of pro-inflammatory cytokines, adhesion molecules and the activation of TLR4/Myd88/NF-κB signaling pathway were determined.
RESULTS
RESULTS
The results showed luteolin significantly inhibited LPS-induced leukocyte adhesion, hydrogen peroxide production and mast cell degranulation, and increased intestinal microcirculation blood flow and ameliorated pathological changes in the mesenteric artery and the small intestine. Furthermore, luteolin inhibited the release of pro-inflammatory cytokines, the expression of TLR4, Myd88, ICAM-1, and VCAM-1, the phosphorylation of IκB-α and NF-κB/p65 in LPS stimulated EA.hy926.
CONCLUSIONS
CONCLUSIONS
Our findings revealed that it is likely that luteolin can ameliorate microcirculatory disturbance. The inhibitory effects of luteolin on the leukocyte adhesion stimulated by LPS, which participates in the development of microcirculatory disturbance, are mediated through the regulation of the TLR4/Myd88/NF-κB signaling pathway.
Identifiants
pubmed: 33446171
doi: 10.1186/s12906-020-03196-9
pii: 10.1186/s12906-020-03196-9
pmc: PMC7807763
doi:
Substances chimiques
Lipopolysaccharides
0
Luteolin
KUX1ZNC9J2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Subventions
Organisme : Natural Science Foundation of Zhejiang Province
ID : No.LQ18H280003
Organisme : National Natural Science Foundation of China
ID : No. 81873036
Organisme : National Natural Science Foundation of China
ID : 82003977
Références
Carcinogenesis. 2010 Oct;31(10):1822-32
pubmed: 20400476
Biochem Pharmacol. 2001 Dec 1;62(11):1537-44
pubmed: 11728390
Sci Rep. 2018 Sep 11;8(1):13600
pubmed: 30206272
Pharm Res. 1996 May;13(5):649-62
pubmed: 8860419
Med Sci Monit. 2016 Dec 28;22:5173-5180
pubmed: 28029146
J Immunol. 2010 May 1;184(9):5242-52
pubmed: 20363969
Immunology. 2005 Jul;115(3):375-87
pubmed: 15946255
Clin Hemorheol Microcirc. 2006;34(1-2):103-8
pubmed: 16543624
Brain Res Bull. 2015 Oct;119(Pt A):1-11
pubmed: 26361743
Drug Des Devel Ther. 2016 Jun 01;10:1829-35
pubmed: 27330276
J Cardiovasc Pharmacol. 2014 Apr;63(4):323-32
pubmed: 24710469
Immunology. 2008 Mar;123(3):398-410
pubmed: 17922833
Biochem Pharmacol. 2018 Aug;154:384-396
pubmed: 29883707
Curr Hypertens Rep. 2017 Apr;19(4):36
pubmed: 28444579
PLoS One. 2013;8(2):e53474
pubmed: 23405070
Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2786-98
pubmed: 17704289
J Immunol. 1998 Dec 15;161(12):6861-70
pubmed: 9862718
Evid Based Complement Alternat Med. 2015;2015:364876
pubmed: 26495010
J Ethnopharmacol. 2018 Oct 28;225:342-358
pubmed: 29801717
J Cell Biochem. 2010 Nov 1;111(4):865-71
pubmed: 20665542
Nutr Res Pract. 2013 Dec;7(6):423-9
pubmed: 24353826
Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2705-11
pubmed: 15331369
Life Sci. 2007 Jul 19;81(6):509-18
pubmed: 17655881
Front Pharmacol. 2018 Sep 25;9:1094
pubmed: 30319424
Eur J Epidemiol. 2018 Dec;33(12):1219-1228
pubmed: 30182323
Biol Reprod. 2012 Feb 29;86(2):51
pubmed: 22053092
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
J Ethnopharmacol. 2013 Nov 25;150(2):507-13
pubmed: 24080032
J Nutr Biochem. 2015 Mar;26(3):293-302
pubmed: 25577468
Eur J Nutr. 2014 Feb;53(1):269-75
pubmed: 23604495
Acta Derm Venereol. 2002;82(1):25-9
pubmed: 12013193
Food Chem. 2012 Dec 15;135(4):2366-71
pubmed: 22980814
J Cell Biochem. 2018 Nov;119(10):8410-8418
pubmed: 29932250
Am J Physiol. 1997 Jun;272(6 Pt 2):H2976-82
pubmed: 9227576
World J Gastroenterol. 2007 Jul 14;13(26):3581-91
pubmed: 17659708
Neurochem Res. 2018 Oct;43(10):1905-1913
pubmed: 30088237
Aliment Pharmacol Ther. 2017 Nov;46(9):825-835
pubmed: 29023881
Evid Based Complement Alternat Med. 2013;2013:395316
pubmed: 23533479
Cell Physiol Biochem. 2015;37(1):27-34
pubmed: 26278073
J Neurochem. 2018 Mar;144(5):517-526
pubmed: 28950410
J Immunol. 1994 Apr 1;152(7):3570-7
pubmed: 7511651
Cytokine. 2015 Aug;74(2):181-9
pubmed: 25846205
Mini Rev Med Chem. 2009 Jan;9(1):31-59
pubmed: 19149659
Clin Chest Med. 2016 Jun;37(2):263-75
pubmed: 27229643
Shock. 2009 Sep;32(3):310-6
pubmed: 19174743
Microcirculation. 2013 Oct;20(7):617-28
pubmed: 23551520
Curr Opin Hematol. 2006 Jan;13(1):34-9
pubmed: 16319685
Inflammopharmacology. 2019 Aug;27(4):773-780
pubmed: 30276558
Chonnam Med J. 2011 Aug;47(2):104-10
pubmed: 22111069
Shock. 2008 Feb;29(2):205-11
pubmed: 17667359